Promore Pharma AB (publ) comments that a number of measures have been taken to reduce the Company's costs, which includes the discontinuation of the ensereptide project and the termination of the Company's key personnel.
The board of Promore Pharma has therefore made the decision to give notice of termination to the company’s CEO, Jonas Ekblom, as well as the key people who are engaged on a consulting basis.